BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31278686)

  • 21. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.
    Thosani S; Ayala-Ramirez M; Palmer L; Hu MI; Rich T; Gagel RF; Cote G; Waguespack SG; Habra MA; Jimenez C
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1813-9. PubMed ID: 24030942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
    Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
    Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
    Kumarasamy VM; Shin YJ; White J; Sun D
    BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review.
    Fallahi P; Patrizio A; Stoppini G; Elia G; Ragusa F; Paparo SR; Balestri E; Mazzi V; Botrini C; Varricchi G; Ulisse S; Ghionzoli M; Antonelli A; Ferrari SM
    Curr Oncol; 2023 Nov; 30(12):10237-10248. PubMed ID: 38132379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation.
    Vantyghem MC; Pigny P; Leteurtre E; Leclerc L; Bauters C; Douillard C; D'Herbomez M; Carnaille B; Proye C; Wemeau JL; Lecomte-Houcke M
    Thyroid; 2004 Oct; 14(10):842-7. PubMed ID: 15588381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
    Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catecholamine crisis as a first manifestation of familial bilateral pheochromocytoma caused by RET proto-oncogene mutation in codon C 634R.
    Zwolak A; Rudzki G; Świrska J; Dudzińska M; Daniluk J; Tarach J
    Endokrynol Pol; 2015; 66(5):462-8. PubMed ID: 26457501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma.
    Moraitis AG; Martucci VL; Pacak K
    Endocr Pract; 2014 Feb; 20(2):176-87. PubMed ID: 24449662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
    Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
    Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
    Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
    Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.
    de Graaff E; Srinivas S; Kilkenny C; D'Agati V; Mankoo BS; Costantini F; Pachnis V
    Genes Dev; 2001 Sep; 15(18):2433-44. PubMed ID: 11562352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
    Griffith C; Zhang S; Mukhopadhyay S
    Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mice conditionally expressing RET(C618F) mutation display C cell hyperplasia and hyperganglionosis of the enteric nervous system.
    Okamoto M; Yoshioka Y; Maeda K; Bito Y; Fukumoto T; Uesaka T; Enomoto H
    Genesis; 2019 May; 57(5):e23292. PubMed ID: 30884088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ghrelin and obestatin in thyroid gland - immunohistochemical expression in nodular goiter, papillary and medullary cancer.
    Gurgul E; Kasprzak A; Blaszczyk A; Biczysko M; Surdyk-Zasada J; Seraszek-Jaros A; Ruchala M
    Folia Histochem Cytobiol; 2015; 53(1):19-25. PubMed ID: 25765090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
    Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.